Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE versus CEFUROXIME AXETIL.
Head-to-head clinical analysis: CEFTRIAXONE versus CEFUROXIME AXETIL.
CEFTRIAXONE vs CEFUROXIME AXETIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cefuroxime axetil is a prodrug that is hydrolyzed to cefuroxime, a second-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 24 hours; maximum 4 g/day.
250–500 mg orally twice daily; for severe infections (e.g., pneumonia), 500 mg twice daily; for uncomplicated urinary tract infections, 250 mg twice daily; for Lyme disease, 500 mg twice daily for 20 days.
None Documented
None Documented
Clinical Note
moderateCeftriaxone + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftriaxone."
Clinical Note
moderateCeftriaxone + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftriaxone."
Clinical Note
moderateWarfarin + Ceftriaxone
"Warfarin may increase the anticoagulant activities of Ceftriaxone."
Clinical Note
moderatePhenprocoumon + Ceftriaxone
Terminal half-life: 5.8-8.7 hours in adults; prolonged to 12-24 hours in neonates and 30-90 hours in severe renal impairment.
1.2-1.6 hours (normal renal function); prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min). For oral cefuroxime axetil, consider absorption and conversion to active cefuroxime.
Renal (33-67% unchanged) and biliary (up to 40%) with fecal elimination. In neonates, renal excretion is lower (~20%).
Renal: 70-90% unchanged by glomerular filtration and tubular secretion; biliary/fecal: <10%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftriaxone."